GuidelineDrugs2015
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.
Guideline in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Best evidence summary for the management of epidermal growth factor receptor inhibitor-induced skin toxicity symptoms in cancer patients.Frontiers in medicine · 2025Pooled it
- Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.Frontiers in oncology · 2021Pooled it
- A technical appraisal of guidelines for the management of skin rash in patients on chemotherapy and targeted therapy.BMC health services research · 2019Pooled it
- Trial
- Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-IIIJCO precision oncology · 2021Trial
- A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Trial
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.JAMA oncology · 2018Trial
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial.Integrative cancer therapiesTrial
- JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury.Nature communications · 2026Article
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Chinese medical journal · 2026Review
- Safety Profile and Tumor Response of EGFR-TKIs in Clinical Practice: A Real-World Study in Thailand.Journal of clinical medicine · 2026Article
- The evolution of cancer therapies and their Implications for health technology assessment in Australia.Cost effectiveness and resource allocation : C/E · 2026Review
- Epidermal growth factor receptor signaling modulates postoperative pain and inflammatory responses.Frontiers in immunology · 2026Review
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment.Clinical and translational science · 2025Review
- The role of nursing in enhancing quality of life for lung cancer patients receiving targeted and immunotherapy: Challenges, opportunities, and future directions.Human vaccines & immunotherapeutics · 2025Review
- Mitigation and management of adverse events associated with amivantamab therapy.The oncologist · 2025Review
- Best evidence summary for preventing and preventing epidermal growth factor receptor inhibitors induced paronychia in cancer patients.Frontiers in oncology · 2025Article
- Nuclear Receptors and Stress Response Pathways Associated with the Development of Oral Mucositis Induced by Antineoplastic Agents.Pharmaceuticals (Basel, Switzerland) · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient's quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.